CLINICAL TRIALNot yet recruiting
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
Treatments or procedures
· TNX-102 SL
· Placebo SL Tablet
How success will be measured
This study is new. We’ll notifiy you when this trial starts recruiting.
0REPLY1 YEAR AGO